What Is Transarterial Chemoembolization (TACE)? A 2026 Overview

Transarterial chemoembolization (TACE) is a localized treatment that blocks the blood vessels feeding a liver tumor, effectively starving it, and serves as the core treatment for intermediate-stage liver cancer, which typically involves multiple tumors within the liver.

Key Takeaways

• TACE is a localized treatment that starves tumors by blocking the hepatic arteries that supply them with nutrients, and it is the central treatment for intermediate-stage liver cancer involving multiple tumors within the liver.
• It is considered when the tumor cannot be surgically removed but remains confined within the liver, and when liver function and portal blood flow are sufficient to tolerate the procedure.
• Fever, abdominal pain, nausea, and fatigue are common for a day or two after the procedure. These symptoms typically resolve within a few days, and patients are usually able to return home within about 10 days.
• Whether TACE can be performed depends not only on tumor size but also on liver function grade (Child-Pugh), and the final treatment decision is made by the attending medical team.
• Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registration Statistics, 2019–2023), which is a nationwide statistic, not a figure for any individual institution.

How Does TACE Work?

• TACE works by locating and blocking the artery that supplies blood to the liver tumor, cutting off its nutrient supply and effectively starving it.
• Because liver cancer most often develops on a background of chronic hepatitis or cirrhosis, eligibility for treatment depends not only on cancer stage but also on liver function grade and portal pressure. This means that tumors of the same size and number may or may not be treatable with TACE depending on underlying liver function.
• Radioembolization may be used alongside or instead of TACE, and combinations with stereotactic radiotherapy, particle therapy, or systemic drug therapy — or trying one of these first — are also considered depending on the case.

When Is TACE Recommended?

• Liver cancer treatment pathways are divided by stage. For very early and early-stage disease, where tumors are small, few in number, and liver function is good, liver resection, radiofrequency ablation, or liver transplantation are generally considered first.
• For intermediate-stage disease, where multiple tumors exist within the liver, TACE is the core treatment. Candidates are patients whose tumors cannot be resected but remain confined within the liver without spreading outside it, and whose liver function and portal blood flow can withstand the procedure.
• For advanced-stage disease involving vascular invasion or spread beyond the liver, systemic drug therapy (such as combinations of immune checkpoint inhibitors and anti-angiogenic agents) becomes the primary approach, and TACE is not generally the first-line option.
• When liver function has significantly declined, the procedure itself may further damage the liver, so symptom control, preservation of liver function, and evaluation for transplant candidacy are prioritized instead.

What Side Effects and Recovery Time Can Be Expected After the Procedure?

• Following embolization procedures, including TACE, fever, abdominal pain, nausea, and fatigue are common for a day or two. These reactions are generally described as an expected part of the recovery process.
• Symptoms typically subside within a few days, and the general goal is for patients to be in a condition suitable for returning home within about 10 days. However, in patients with borderline liver function, jaundice, ascites, or altered consciousness can occur, so close monitoring during hospitalization is necessary.
• For patients who have undergone multiple rounds of TACE elsewhere, such as in China, with diminishing response, switching to systemic drug therapy or radiotherapy is considered. The number and extent of prior procedures, along with imaging records, serve as the basis for this decision.

What Does Follow-Up Monitoring Look Like After TACE?

• Stage 1: In the first 1–2 years after treatment, contrast-enhanced CT or MRI scans and tumor marker tests such as AFP are repeated at intervals of a few months.
• Stage 2: The interval between follow-up visits is gradually extended thereafter.
• Stage 3: For patients with chronic hepatitis B or C, antiviral treatment and liver function tests continue for life.
• Because liver cancer can recur in other parts of the liver beyond the treated area, follow-up intervals tend to be more frequent than for other cancers. After returning home, patients may receive a handover document from their local medical team outlining the timing and items for the next check-up.

FAQ — Is a Biopsy Required to Receive TACE?

Not necessarily. Liver cancer is often diagnosed based on the characteristic blood flow pattern seen on contrast-enhanced CT or MRI (strong enhancement in the arterial phase followed by washout) combined with tumor markers such as AFP, meaning a diagnosis can often be confirmed without a biopsy. A biopsy is only performed when imaging findings are ambiguous or metastasis from another cancer is suspected.

FAQ — How Long Is the Typical Stay in Korea for TACE?

The general target length of stay for radiofrequency ablation and embolization procedures (including TACE) is around 10 days. However, this can vary depending on the individual's rate of liver function recovery and the extent of the procedure, and the timing of return travel is determined only after confirmation by the attending medical team.

Sources and Notes

• This article was written based on the National Cancer Registration Statistics 2019–2023 (Korea Central Cancer Registry, National Cancer Center), the National Cancer Information Center, and liver cancer–related materials at the level of NCCN patient guidelines.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment decisions should always be made in consultation with a medical professional.